ABL Bio Statistics

Total Valuation

ABL Bio has a market cap or net worth of KRW 1.67 trillion. The enterprise value is 1.58 trillion.

Market Cap	1.67T
Enterprise Value	1.58T

Important Dates

The last earnings date was Wednesday, March 12, 2025.

Earnings Date	Mar 12, 2025
Ex-Dividend Date	n/a

Share Statistics

ABL Bio has 48.53 million shares outstanding. The number of shares has increased by 0.37% in one year.

Current Share Class	n/a
Shares Outstanding	48.53M
Shares Change (YoY)	+0.37%
Shares Change (QoQ)	+0.30%
Owned by Insiders (%)	30.26%
Owned by Institutions (%)	19.87%
Float	33.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	49.53
PB Ratio	10.12
P/TBV Ratio	10.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-28.40
EV / Sales	47.21
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-20.11

Financial Position

The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.26.

Current Ratio	2.28
Quick Ratio	2.24
Debt / Equity	0.26
Debt / EBITDA	n/a
Debt / FCF	-0.56
Interest Coverage	-1,647.36

Financial Efficiency

Return on equity (ROE) is -46.01% and return on invested capital (ROIC) is -22.56%.

Return on Equity (ROE)	-46.01%
Return on Assets (ROA)	-18.93%
Return on Invested Capital (ROIC)	-22.56%
Return on Capital Employed (ROCE)	-35.21%
Revenue Per Employee	327.48M
Profits Per Employee	-544.41M
Employee Count	102
Asset Turnover	0.17
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +27.12% in the last 52 weeks. The beta is 0.91, so ABL Bio's price volatility has been similar to the market average.

Beta (5Y)	0.91
52-Week Price Change	+27.12%
50-Day Moving Average	37,576.00
200-Day Moving Average	32,048.25
Relative Strength Index (RSI)	40.33
Average Volume (20 Days)	872,553

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABL Bio had revenue of KRW 33.40 billion and -55.53 billion in losses. Loss per share was -1,156.34.

Revenue	33.40B
Gross Profit	33.34B
Operating Income	-59.38B
Pretax Income	-55.53B
Net Income	-55.53B
EBITDA	-56.97B
EBIT	-59.38B
Loss Per Share	-1,156.34

Full Income Statement

Balance Sheet

The company has 141.51 billion in cash and 43.66 billion in debt, giving a net cash position of 97.85 billion or 2,016.34 per share.

Cash & Cash Equivalents	141.51B
Total Debt	43.66B
Net Cash	97.85B
Net Cash Per Share	2,016.34
Equity (Book Value)	167.28B
Book Value Per Share	3,404.81
Working Capital	80.79B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -69.40 billion and capital expenditures -9.02 billion, giving a free cash flow of -78.43 billion.

Operating Cash Flow	-69.40B
Capital Expenditures	-9.02B
Free Cash Flow	-78.43B
FCF Per Share	-1,616.10

Full Cash Flow Statement

Margins

Gross margin is 99.82%, with operating and profit margins of -177.76% and -166.24%.

Gross Margin	99.82%
Operating Margin	-177.76%
Pretax Margin	-166.24%
Profit Margin	-166.24%
EBITDA Margin	-170.55%
EBIT Margin	-177.76%
FCF Margin	n/a

Dividends & Yields

ABL Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.37%
Shareholder Yield	-0.37%
Earnings Yield	-3.32%
FCF Yield	-4.69%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABL Bio has an Altman Z-Score of 9.53.

Altman Z-Score	9.53
Piotroski F-Score	n/a